294 related articles for article (PubMed ID: 36142419)
1. Interaction between Alzheimer's Disease and Cerebral Small Vessel Disease: A Review Focused on Neuroimaging Markers.
Kim SE; Kim HJ; Jang H; Weiner MW; DeCarli C; Na DL; Seo SW
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142419
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Extent and Role of Tau in Subcortical Vascular Cognitive Impairment Using 18F-AV1451 Positron Emission Tomography Imaging.
Kim HJ; Park S; Cho H; Jang YK; San Lee J; Jang H; Kim Y; Kim KW; Ryu YH; Choi JY; Moon SH; Weiner MW; Jagust WJ; Rabinovici GD; DeCarli C; Lyoo CH; Na DL; Seo SW
JAMA Neurol; 2018 Aug; 75(8):999-1007. PubMed ID: 29799981
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Amyloid-β or Tau on Cognitive Change in the Presence of Severe Cerebrovascular Disease.
Jang H; Kim HJ; Choe YS; Kim SJ; Park S; Kim Y; Kim KW; Lyoo CH; Cho H; Ryu YH; Choi JY; DeCarli C; Na DL; Seo SW;
J Alzheimers Dis; 2020; 78(2):573-585. PubMed ID: 33016911
[TBL] [Abstract][Full Text] [Related]
4. Distinct amyloid distribution patterns in amyloid positive subcortical vascular cognitive impairment.
Jang H; Park JY; Jang YK; Kim HJ; Lee JS; Na DL; Noh Y; Lockhart SN; Seong JK; Seo SW
Sci Rep; 2018 Nov; 8(1):16178. PubMed ID: 30385819
[TBL] [Abstract][Full Text] [Related]
5. Cerebral small vessel disease and the risk of Alzheimer's disease: A systematic review.
Liu Y; Braidy N; Poljak A; Chan DKY; Sachdev P
Ageing Res Rev; 2018 Nov; 47():41-48. PubMed ID: 29898422
[TBL] [Abstract][Full Text] [Related]
6. Application of an amyloid and tau classification system in subcortical vascular cognitive impairment patients.
Jang H; Kim HJ; Park S; Park YH; Choe Y; Cho H; Lyoo CH; Yoon U; Lee JS; Kim Y; Kim SJ; Kim JP; Jung YH; Ryu YH; Choi JY; Moon SH; Seong JK; DeCarli C; Weiner MW; Lockhart SN; Cho SH; Na DL; Seo SW
Eur J Nucl Med Mol Imaging; 2020 Feb; 47(2):292-303. PubMed ID: 31471715
[TBL] [Abstract][Full Text] [Related]
7. Features of Cerebral Small Vessel Disease Contributes to the Differential Diagnosis of Alzheimer's Disease.
Cheng ZZ; Gao F; Lv XY; Wang Q; Wu Y; Sun BL; Shen Y
J Alzheimers Dis; 2023; 91(2):795-804. PubMed ID: 36502328
[TBL] [Abstract][Full Text] [Related]
8. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
9. Cerebral Small Vessel Disease Burden Predicts Neurodegeneration and Clinical Progression in Prodromal Alzheimer's Disease.
Sun Y; Hu HY; Hu H; Huang LY; Tan L; Yu JT;
J Alzheimers Dis; 2023; 93(1):283-294. PubMed ID: 36970905
[TBL] [Abstract][Full Text] [Related]
10. The relationship between amyloid pathology, cerebral small vessel disease, glymphatic dysfunction, and cognition: a study based on Alzheimer's disease continuum participants.
Hong H; Hong L; Luo X; Zeng Q; Li K; Wang S; Jiaerken Y; Zhang R; Yu X; Zhang Y; Lei C; Liu Z; Chen Y; Huang P; Zhang M;
Alzheimers Res Ther; 2024 Feb; 16(1):43. PubMed ID: 38378607
[TBL] [Abstract][Full Text] [Related]
11. Independent effects of amyloid and vascular markers on long-term functional outcomes: An 8-year longitudinal study of subcortical vascular cognitive impairment.
Kang SH; Woo SY; Kim S; Kim JP; Jang H; Koh SB; Na DL; Kim HJ; Seo SW
Eur J Neurol; 2022 Feb; 29(2):413-421. PubMed ID: 34716964
[TBL] [Abstract][Full Text] [Related]
12. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
13. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population.
Xie Q; Ni M; Gao F; Dai LB; Lv XY; Zhang YF; Shi Q; Zhu XX; Xie JK; Shen Y; Wang SC
ACS Chem Neurosci; 2022 May; 13(10):1558-1565. PubMed ID: 35476397
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
[TBL] [Abstract][Full Text] [Related]
15. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
[TBL] [Abstract][Full Text] [Related]
16. Plasma Core Alzheimer's Disease Biomarkers Predict Amyloid Deposition Burden by Positron Emission Tomography in Chinese Individuals with Cognitive Decline.
Ni M; Zhu ZH; Gao F; Dai LB; Lv XY; Wang Q; Zhu XX; Xie JK; Shen Y; Wang SC; Xie Q;
ACS Chem Neurosci; 2023 Jan; 14(1):170-179. PubMed ID: 36547971
[TBL] [Abstract][Full Text] [Related]
17. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
[TBL] [Abstract][Full Text] [Related]
18. Pathophysiology characterization of Alzheimer's disease in South China's aging population: for the Greater-Bay-Area Healthy Aging Brain Study (GHABS).
Liu Z; Shi D; Cai Y; Li A; Lan G; Sun P; Liu L; Zhu Y; Yang J; Zhou Y; Guo L; Zhang L; Deng S; Chen S; Yu X; Chen X; Zhao R; Wang Q; Ran P; Xu L; Zhou L; Sun K; Wang X; Peng Q; Han Y; Guo T
Alzheimers Res Ther; 2024 Apr; 16(1):84. PubMed ID: 38627753
[TBL] [Abstract][Full Text] [Related]
19. White Matter Hyperintensities Potentiate Hippocampal Volume Reduction in Non-Demented Older Individuals with Abnormal Amyloid-β.
Freeze WM; Jacobs HI; Gronenschild EH; Jansen JF; Burgmans S; Aalten P; Clerx L; Vos SJ; van Buchem MA; Barkhof F; van der Flier WM; Verbeek MM; Rikkert MO; Backes WH; Verhey FR;
J Alzheimers Dis; 2017; 55(1):333-342. PubMed ID: 27662299
[TBL] [Abstract][Full Text] [Related]
20. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.
Okafor M; Nye JA; Shokouhi M; Shaw LM; Goldstein F; Hajjar I
J Alzheimers Dis; 2020; 74(2):589-601. PubMed ID: 32065800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
